Pfizer (NYSE:PFE) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Pfizer (NYSE:PFE) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm issued a neutral rating and a $24.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Pfizer’s FY2025 earnings at $2.99 EPS.

A number of other research firms have also commented on PFE. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group reduced their price target on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday, April 8th. Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.57.

Pfizer Price Performance

NYSE PFE opened at $22.80 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company’s 50 day simple moving average is $24.63 and its 200 day simple moving average is $26.01. Pfizer has a 12 month low of $20.92 and a 12 month high of $31.54. The firm has a market capitalization of $129.31 billion, a PE ratio of 16.17, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 earnings per share. As a group, equities research analysts forecast that Pfizer will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.54%. Pfizer’s dividend payout ratio is currently 121.99%.

Insider Activity

In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by company insiders.

Institutional Trading of Pfizer

Several hedge funds have recently added to or reduced their stakes in the business. PSI Advisors LLC lifted its position in shares of Pfizer by 1.4% in the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its holdings in shares of Pfizer by 1.0% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock worth $1,027,000 after acquiring an additional 391 shares during the period. D Orazio & Associates Inc. increased its position in Pfizer by 5.5% during the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after acquiring an additional 391 shares during the period. Lipe & Dalton grew its position in Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 400 shares in the last quarter. Finally, Oliver Luxxe Assets LLC lifted its holdings in shares of Pfizer by 2.2% during the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 401 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.